Cure My Disease

Don't miss your cure!

 Log in / Sign up

Promising drug may halt devastating attacks in rare brain disorder

NCT ID NCT07184840

Recruiting now Disease control Sponsor: Tianjin Medical University General Hospital Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated May 14, 2026 · Updated 26 times

Summary

This study tests whether eculizumab can quickly reduce disability during acute attacks of neuromyelitis optica spectrum disorder (NMOSD), a rare autoimmune disease that damages the brain and spinal cord. About 110 adults who test positive for the AQP4 antibody and are having an attack will receive the drug. The goal is to see if it improves symptoms within 28 days by blocking a part of the immune system that causes nerve damage.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NEUROMYELITIS OPTICA SPECTRUM DISORDER ATTACK are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Tianjin Medical University General Hospital

    RECRUITING

    Tianjin, Tianjin Municipality, 300052, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

NEUROMYELITIS OPTICA SPECTRUM DISORDER ATTACK